메뉴 건너뛰기




Volumn 30, Issue 7, 2014, Pages 1219-1230

Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A 12-week, randomized, placebo-controlled, phase II study

Author keywords

Japanese; Luseogliflozin; Monotherapy; Phase II clinical study; Placebo; Sodium glucose cotransporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

ACETYLGLUCOSAMINIDASE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CARBOHYDRATE; CORTICOSTEROID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE BODY; LUSEOGLIFLOZIN; ORAL ANTIDIABETIC AGENT; PLACEBO; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SORBITOL;

EID: 84902245089     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.901943     Document Type: Article
Times cited : (53)

References (27)
  • 1
    • 77951089891 scopus 로고    scopus 로고
    • International Diabetes Federation. 5th Edition 2012 Update: New Estimates for 2012 of Diabetes Prevalence Mortality, and Healthcare Expenditure
    • International Diabetes Federation. IDF Diabetes Atlas 5th Edition 2012 Update: New Estimates for 2012 of Diabetes Prevalence, Mortality, and Healthcare Expenditure. 2012
    • (2012) IDF Diabetes Atlas
  • 2
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the american diabetes association (ada and the european association for the study of diabetes (easd
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
    • (2012) Diabetes Care , vol.35 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 3
    • 84857226676 scopus 로고    scopus 로고
    • DPP-4 inhibition and islet function
    • Ahren B. DPP-4 inhibition and islet function. J Diabetes Investig 2012;3:3-10
    • (2012) J Diabetes Investig , vol.3 , pp. 3-10
    • Ahren, B.1
  • 4
    • 84878360808 scopus 로고    scopus 로고
    • Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
    • Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
    • (2013) J Diabetes Investig , vol.4 , pp. 108-130
    • Seino, Y.1    Yabe, D.2
  • 5
    • 84871651233 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
    • Kubota A, Maeda H, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig 2012;3:503-9
    • (2012) J Diabetes Investig , vol.3 , pp. 503-509
    • Kubota, A.1    Maeda, H.2    Kanamori, A.3
  • 6
    • 84904597331 scopus 로고    scopus 로고
    • Factors influencing durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea
    • published online 11 February 2014 doi:10.1111/jdi.12182
    • Kubota A, Yabe D, Kanamori A, et al. Factors influencing durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Investig 2014: Published online 11 February 2014, doi:10.1111/jdi.12182
    • (2014) J Diabetes Investig
    • Kubota, A.1    Yabe, D.2    Kanamori, A.3
  • 7
    • 84859739099 scopus 로고    scopus 로고
    • Expression of Na-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences
    • Sabolic I, Vrhovac I, Eror DB, et al. Expression of Na-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 2012;302:C1174-88
    • (2012) Am J Physiol Cell Physiol , vol.302
    • Sabolic, I.1    Vrhovac, I.2    Eror, D.B.3
  • 8
    • 84865400266 scopus 로고    scopus 로고
    • Role of sodium-glucose transporters in glucose uptake of the intestine and kidney
    • Harada N, Inagaki N. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Investig 2012;3:352-3
    • (2012) J Diabetes Investig , vol.3 , pp. 352-35353
    • Harada, N.1    Inagaki, N.2
  • 9
    • 67349189212 scopus 로고    scopus 로고
    • Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications
    • Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7
    • (2009) Kidney Int , vol.75 , pp. 1272-1277
    • Bakris, G.L.1    Fonseca, V.A.2    Sharma, K.3
  • 10
    • 79952404360 scopus 로고    scopus 로고
    • SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
    • Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011;60:890-8
    • (2011) Diabetes , vol.60 , pp. 890-898
    • Jurczak, M.J.1    Lee, H.Y.2    Birkenfeld, A.L.3
  • 11
    • 78651406659 scopus 로고    scopus 로고
    • SGLT2 mediates glucose reabsorption in the early proximal tubule
    • Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22:104-12
    • (2011) J Am Soc Nephrol , vol.22 , pp. 104-112
    • Vallon, V.1    Platt, K.A.2    Cunard, R.3
  • 12
    • 84872400230 scopus 로고    scopus 로고
    • Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
    • Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013;304:F156-67
    • (2013) Am J Physiol Renal Physiol , vol.304
    • Vallon, V.1    Rose, M.2    Gerasimova, M.3
  • 13
    • 64749089393 scopus 로고    scopus 로고
    • Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus
    • Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14:782-90
    • (2008) Endocr Pract , vol.14 , pp. 782-790
    • Abdul-Ghani, M.A.1    DeFronzo, R.A.2
  • 14
    • 83655193529 scopus 로고    scopus 로고
    • The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia
    • DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
    • (2012) Diabetes Obes Metab , vol.14 , pp. 5-14
    • DeFronzo, R.A.1    Davidson, J.A.2    Del Prato, S.3
  • 15
    • 75149196250 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
    • Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
    • (2010) J Clin Endocrinol Metab , vol.95 , pp. 34-42
    • Nair, S.1    Wilding, J.P.2
  • 16
    • 84864283226 scopus 로고    scopus 로고
    • SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects
    • Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 495-502
    • Ferrannini, E.1    Solini, A.2
  • 17
    • 77951143723 scopus 로고    scopus 로고
    • 1S-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl] -1-Thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment
    • Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-Anhydro-1-[5-(4- ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-Thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010;53:3247-61
    • (2010) J Med Chem , vol.53 , pp. 3247-3261
    • Kakinuma, H.1    Oi, T.2    Hashimoto-Tsuchiya, Y.3
  • 18
    • 79961228970 scopus 로고    scopus 로고
    • TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
    • Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011;164:181-91
    • (2011) Br J Pharmacol , vol.164 , pp. 181-191
    • Yamamoto, K.1    Uchida, S.2    Kitano, K.3
  • 19
    • 84898890575 scopus 로고    scopus 로고
    • Safety, Pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: A randomized, single-blind, placebo-controlled trial
    • published online 18 February 2014 doi:10.1007/s12325-014-0102-3
    • Sasaki T, Seino Y, Fukatsu A, et al. Safety, Pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: A randomized, single-blind, placebo-controlled trial. Adv Ther 2014: Published online 18 February 2014, doi:10.1007/s12325-014-0102-3
    • (2014) Adv Ther
    • Sasaki, T.1    Seino, Y.2    Fukatsu, A.3
  • 20
    • 84903569376 scopus 로고    scopus 로고
    • Ts-071 a novel potent and highly selective renal sodium-glucose co-Transporter 2 (sglt2) inhibitor increases urinary glucose excretion and reduces plasma glucose levels in japanese patients with type 2 diabetes mellitus
    • 12-16 September 2011. Lisbon, Portugal
    • Sasaki T, Seino Y, Fukatsu A, et al. TS-071, a novel potent and highly selective renal sodium-glucose co-Transporter 2 (SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. 47th European Association for the Study of Diabetes (EASD) Annual Meeting, 12-16 September 2011. Lisbon, Portugal, 2011
    • (2011) 47th European Association For The Study Of Diabetes (EASD) Annual Meeting
    • Sasaki, T.1    Seino, Y.2    Fukatsu, A.3
  • 21
    • 84861993148 scopus 로고    scopus 로고
    • Risk factors for type 2 diabetes: Lessons learned from japanese americans in seattle
    • Fujimoto WY, Boyko EJ, Hayashi T, et al. Risk factors for type 2 diabetes: Lessons learned from Japanese Americans in Seattle. J Diabetes Investig 2012;3:212-24
    • (2012) J Diabetes Investig , vol.3 , pp. 212-224
    • Fujimoto, W.Y.1    Boyko, E.J.2    Hayashi, T.3
  • 23
    • 84857217561 scopus 로고    scopus 로고
    • International clinical harmonization of glycated hemoglobin in japan: From japan diabetes society to national glycohemoglobin standardization program values
    • Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012;3:8-10
    • (2012) Diabetol Int , vol.3 , pp. 8-10
    • Kashiwagi, A.1    Kasuga, M.2    Araki, E.3
  • 24
    • 65349196064 scopus 로고    scopus 로고
    • Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes
    • List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
    • (2009) Diabetes Care , vol.32 , pp. 650-657
    • List, J.F.1    Woo, V.2    Morales, E.3
  • 25
    • 84865479822 scopus 로고    scopus 로고
    • Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans
    • Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61:2199-204
    • (2012) Diabetes , vol.61 , pp. 2199-2204
    • Liu, J.J.1    Lee, T.2    DeFronzo, R.A.3
  • 26
    • 84863610946 scopus 로고    scopus 로고
    • Effect of canagliflozin, a sodium glucose co-Transporter 2 (sglt2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study
    • Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-Transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012;28:1167-71
    • (2012) Curr Med Res Opin , vol.28 , pp. 1167-1171
    • Nicolle, L.E.1    Capuano, G.2    Ways, K.3
  • 27
    • 84863617006 scopus 로고    scopus 로고
    • Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-Transporter 2 inhibitor
    • Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-Transporter 2 inhibitor. Curr Med Res Opin 2012;28:1173-8.
    • (2012) Curr Med Res Opin , vol.28 , pp. 1173-1178
    • Nyirjesy, P.1    Zhao, Y.2    Ways, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.